electroCore to Announce Third Quarter 2022 Financial Results on November 3
27 oct. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
SportGait Partners With the Carrick Institute, Incorporating Cutting-Edge Concussion Support and Recovery Technology
26 oct. 2022 14h00 HE
|
SportGait
WILMINGTON, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- SportGait, the brain wellness and medical technology company, proudly announced today a partnership with The Carrick Institute, world leader in...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
20 oct. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical...
electroCore Provides Select Third Quarter 2022 Financial Guidance
14 oct. 2022 16h01 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary...
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
11 oct. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury
11 oct. 2022 08h00 HE
|
Incannex Healthcare
MELBOURNE, Australia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique...
Odyssey Health, Inc. Provides Recap on Concussion Drug Development
06 oct. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program
30 sept. 2022 18h28 HE
|
Odyssey Health, Inc
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the “Company” “Odyssey”) a company focused on developing a unique...
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
28 sept. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
New Study Reveals Effective Treatment for Children Suffering From Persistent Post-Concussion Syndrome
23 sept. 2022 13h51 HE
|
Aviv Clinics
ORLANDO, Fla., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Today, Aviv Clinics highlights a new study published in Scientific Reports showing an effective treatment to heal damaged brain tissue and relieve...